Skip to content
Find an ETF
← All ETFs

Available in 10 markets

State Street® SPDR® S&P® Pharmaceuticals ETF

SPDR · US78464A7220

State Street® SPDR® S&P® Pharmaceuticals ETF is an exchange-traded fund (ETF) from SPDR, traded under the ticker XPH (ISIN US78464A7220). One trade buys a whole basket of holdings, so your money is spread out instead of riding on a single company. At its core it is a focused, thematic fund: it concentrates on the health care part of the market,…

· Tracks the S&P Pharmaceuticals Select Industry Index index ?
Equity ?Unknown Physical ?United States ?
Mid-range feeOwns the shares directlyOtherBroadly spread
Find funds like this
SPDR fundsDomiciled in United StatesUnknownPhysically replicatedOther stocksYearly fee under 0.5%

Opens the screener with this filter applied.

Fund size (AUM) ?
€403M
1-year return ?
+32.5%
Price Return · to 2026-10-22
Yearly fee (TER) ?
0.35%
All-in cost ≈ 0.00%

About this fund

What you own

The S&P Pharmaceuticals Select Industry Index index is the benchmark this fund aims to copy. By holding it, this fund gives you a stake in around 64 companies across Other in a single purchase.

How it works

The fund actually buys every share in the index it tracks (full replication).

Read more

Owning every holding keeps things transparent — what is in the index is what the fund actually owns. It can be a touch costlier to run for indexes with thousands of tiny positions, since the fund has to buy and maintain them all. There is no swap bank involved, so there is no extra “what if the partner fails” question to weigh.

Cost

0.35%Yearly fee (TER)
0.00%All-in cost

The yearly running cost of the fund, shown as a % of your money. Lower is cheaper.

Read more

For example, a 0.20% fee works out at €0.20 a year for every €100 invested — that’s a generic illustration of the mechanic, not this fund’s own fee. It is skimmed quietly from inside the fund a little each day, so you never get a bill — but it drags on your return every year you hold. On a broad index ETF it is usually a small fraction of a percent; the gap between a cheap and a pricey fund looks tiny on day one but compounds over decades, which is why it is worth a glance.

Fund facts

Index tracked ?
S&P Pharmaceuticals Select Industry Index
Replication ?
Physical
Full — buys every share
Launched
Jun 2006
20-year track record

Performance

98.299.2100101102202620262026

Growth of $100 invested — both lines start at $100.

State Street® SPDR® S&P® Pharmaceuticals ETF Average S&P Pharmaceuticals Select Industry Index ETF (funds we track) ?

Compared with the average fund tracking the same index — our own data, not the licensed index itself.

YTD+14.8%
1 year+32.5%
3 years+21.1%
5 years+6.0%

Return, year by year

-11.3
+1.6
+3.3
+30.3
'22'23'24'25
3 of 4 up yearsBest: 2025 +30.3%Worst: 2022 -11.3%Calendar-year total returns, in USD

How bumpy has it been?

23.4%
Volatility (1y) ?
How much the price swings year to year — lower is calmer.
-24.1%
Worst drop (3y) ?
The biggest fall from a peak over the last three years.
1.00
Return for the risk (3y) ?
Reward earned per unit of bumpiness.

The bigger picture

+24.3%
Since inception
Total growth since launch — about +4.2% a year.
+70.1%
Best 12 months
The strongest one-year stretch on record.
-21.0%
Worst 12 months
The weakest one-year stretch on record.
-33.7%
Worst fall on record ?
It clawed back in about 25 months.

What's inside

By sector ?

Health Care79.4%
Cash/Other14.6%
Corporate3.0%
Consumer Staples3.0%

The 10 biggest holdings make up 21.7% of the fund — the rest is spread across roughly 54 more companies.

Top 10 holdings

#CompanyWeight
1XERIS BIOPHARMA HOLDINGS INC2.5%
2VERADERMICS INC2.4%
3AMNEAL PHARMACEUTICALS INC2.3%
4LIGAND PHARMACEUTICALS2.2%
5VIATRIS INC2.1%
6INDIVIOR PHARMACEUTICALS INC2.0%
7PERRIGO CO PLC2.0%
8ELI LILLY + CO2.0%
9ANI PHARMACEUTICALS INC2.0%
10PFIZER INC2.0%

Where to buy this fund

Set from your language & location — change it if it's wrong.

Where it trades

ExchangeTickerCurrency
NYSEXPHUSD★ Primary
EUR listings
FrankfurtSSGEEUR
USD listings
B2XPHUSDUSD
B4XPHUSDUSD
E1XPHGBPUSD
E1XPHRUBUSD
E1XPHUSDUSD
EOXPHRUBUSD
ERXPHUSD
ERXPHEURUSD
EUXPHUSDUSD
EUXPHRUBUSD
EUXPHGBPUSD
EUXPH1USD
GHSSGEUSD
GISSGEUSD
MFXPH*USD
MMXPH*USD
MUXPH*USD
NYSE ArcaXPHUSD
OCXPHUSD
THSSGEUSD
UAXPHUSD
UBXPHUSD
UCXPHUSD
UDXPHUSD
UFXPHUSD
UMXPHUSD
USXPHUSD
UTXPHUSD
UXXPHUSD
VFXPHUSD
VGXPHUSD
VJXPHUSD
VKXPHUSD
VPXPHUSD
VTXPHUSD
VYXPHUSD
X1XPHUSDUSD
X1XPHRUBUSD
X1XPHGBPUSD
X2XPHUSDUSD
XAXPHUSDUSD
XAXPHRUBUSD
XAXPHGBPUSD
XBXPHUSDUSD
XEXPHGBPUSD
XEXPHRUBUSD
XEXPHUSDUSD
XFXPHGBPUSD
XFXPHRUBUSD
XFXPHUSDUSD
XGXPHUSDUSD
XGXPHRUBUSD
XGXPHGBPUSD
XHXPHGBPUSD
XHXPHRUBUSD
XHXPHUSDUSD
XJXPHUSDUSD
XJXPHRUBUSD
XJXPHGBPUSD
XLXPHGBPUSD
XLXPHRUBUSD
XLXPHUSDUSD
XOXPHUSDUSD
XOXPHRUBUSD
XOXPHGBPUSD
XQXPHGBPUSD
XQXPHRUBUSD
XQXPHUSDUSD
XSXPHUSDUSD
XSXPHGBPUSD
XTXPHRUBUSD
XUXPHGBPUSD
XUXPHRUBUSD
XUXPHUSDUSD
XVXPHUSDUSD
XVXPHRUBUSD
XVXPHGBPUSD
XWXPHGBPUSD
XWXPHRUBUSD
XWXPHUSDUSD
XXXPHUSDUSD
XXXPHRUBUSD
XXXPHGBPUSD
XZXPHGBPUSD
XZXPHRUBUSD
XZXPHUSDUSD
For serious comparison — full data holdings, percentiles, advanced risk, tilt, flows

Full holdings

As of 2026-10-22 · the fund's own published holdings.

#CompanyWeight
1XERIS BIOPHARMA HOLDINGS INC2.5%
2VERADERMICS INC2.4%
3AMNEAL PHARMACEUTICALS INC2.3%
4LIGAND PHARMACEUTICALS2.2%
5VIATRIS INC2.1%
6INDIVIOR PHARMACEUTICALS INC2.0%
7PERRIGO CO PLC2.0%
8ELI LILLY + CO2.0%
9ANI PHARMACEUTICALS INC2.0%
10PFIZER INC2.0%
11SUPERNUS PHARMACEUTICALS INC2.0%
12INNOVIVA INC2.0%
13ORGANON + CO2.0%
14DEFINIUM THERAPEUTICS INC2.0%
15CORCEPT THERAPEUTICS INC2.0%
16JOHNSON + JOHNSON2.0%
17MERCK + CO. INC.2.0%
18MAZE THERAPEUTICS INC2.0%
19OMEROS CORP2.0%
20BRISTOL MYERS SQUIBB CO1.9%
21SEPTERNA INC1.9%
22ROYALTY PHARMA PLC CL A1.9%
23JAZZ PHARMACEUTICALS PLC1.9%
24ZOETIS INC1.9%
25ELANCO ANIMAL HEALTH INC1.9%
26TARSUS PHARMACEUTICALS INC1.9%
27HARMONY BIOSCIENCES HOLDINGS1.9%
28PRESTIGE CONSUMER HEALTHCARE1.9%
29EDGEWISE THERAPEUTICS INC1.9%
30MBX BIOSCIENCES INC1.9%
31COLLEGIUM PHARMACEUTICAL INC1.8%
32AMYLYX PHARMACEUTICALS INC1.8%
33AXSOME THERAPEUTICS INC1.7%
34ETON PHARMACEUTICALS INC1.7%
35PACIRA BIOSCIENCES INC1.7%
36TREVI THERAPEUTICS INC1.7%
37NUVATION BIO INC1.7%
38HARROW INC1.6%
39ENLIVEN THERAPEUTICS INC1.6%
40AMPHASTAR PHARMACEUTICALS IN1.5%
41ZEVRA THERAPEUTICS INC1.5%
42ALUMIS INC1.5%
43RAPPORT THERAPEUTICS INC1.4%
44LB PHARMACEUTICALS INC1.4%
45WAVE LIFE SCIENCES INC1.4%
46OCULAR THERAPEUTIX INC1.3%
47CORMEDIX INC1.3%
48ALTO NEUROSCIENCE INC1.2%
49PHIBRO ANIMAL HEALTH CORP A1.2%
50AQUESTIVE THERAPEUTICS INC1.2%
51ACLARIS THERAPEUTICS INC1.2%
52PHATHOM PHARMACEUTICALS INC1.1%
53RELMADA THERAPEUTICS INC0.9%
54LIQUIDIA CORP0.9%
55AVALYN PHARMA INC0.9%
56LEXICON PHARMACEUTICALS INC0.8%
57ARVINAS INC0.8%
58EVOLUS INC0.7%
59EYEPOINT INC0.7%
60BIOAGE LABS INC0.7%
61CONTINEUM THERAPEUTICS INC A0.6%
62SSI US GOV MONEY MARKET CLASS0.0%
63CONTRA ESPERION THERAP0.0%
64US DOLLAR0.0%

⭳ Download full holdings (CSV)

How it ranks vs peers

🪙 Cheaper than 32% of similar ETFs📈 Higher 1-yr return than 94%📈 Higher 3-yr return than 83%📈 Higher 5-yr return than 69%📊 Beat its category by 21.2% (1-yr) (category average +11.3%)📊 Beat its category by 5.5% (3-yr) (category average +15.7%)📊 Beat its category by 1.1% (5-yr) (category average +4.9%)

Versus the Equity (stocks) · Other · USD ETFs we track.

Advanced risk

1.47
Sortino (3y) ?
0.88
Calmar (3y) ?
15.1%
Downside deviation ?
67%
Up months (hit rate) ?
$74.06
52-week high ?
$48.30
52-week low ?

Concentration depth

~57 ?
Effective number of holdings

Roughly 64 companies are held, but the largest names carry most of the weight — so it behaves like ~57 equal-sized positions.

Tilt vs a world tracker

Health Care+71.0
Technology-30.6
Financials-18.2
Cash/Other+14.6
Industrials-10.8
Consumer Discretionary-8.5

Percentage points over / under a broad world-equity tracker (not a licensed benchmark).

Similar funds

We found 6 funds that do much the same job as this one. To pick them we matched this fund's asset class and region, then show how close each match is below.

Matched on🌍 Other stocks
Compare side by side
6 similar funds
State Street® SPDR® S&P® Pharmaceuticals ETFSPDRYou're viewingState Street® Technology Select Sector SPDR® ETFSPDRBroader matchState Street® Financial Select Sector SPDR® ETFSPDRBroader matchState Street® Health Care Select Sector SPDR® ETFSPDRBroader matchState Street® Energy Select Sector SPDR® ETFSPDRBroader matchState Street® Industrial Select Sector SPDR® ETFSPDRBroader matchState Street® SPDR® S&P MIDCAP 400® ETF TrustSPDRBroader match
Why it's similarThis is the fund on this page.
StocksUnknownPhysicalCheaper fee
Tracks a different index in the same category.
StocksUnknownPhysicalCheaper fee
Tracks a different index in the same category.
StocksUnknownPhysicalCheaper fee
Tracks a different index in the same category.
StocksUnknownPhysicalCheaper fee
Tracks a different index in the same category.
StocksUnknownPhysicalCheaper fee
Tracks a different index in the same category.
StocksUnknownPhysicalCheaper fee
Tracks a different index in the same category.
Index trackedS&P Pharmaceuticals Select Industry IndexTechnology Select Sector IndexFinancial Select Sector IndexHealth Care Select Sector IndexEnergy Select Sector IndexIndustrial Select Sector IndexS&P MidCap 400 Index
Yearly fee (TER)0.35%0.08%0.08%0.08%0.08%0.08%0.23%
All-in cost0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Fund size€403M€107.4B€46.7B€41.2B€40.1B€27.1B€23B
DomicileUnited StatesUnited StatesUnited StatesUnited StatesUnited StatesUnited StatesUnited States
ReplicationPhysical (full)Physical (full)Physical (full)Physical (full)Physical (full)Physical (full)Physical (full)
3-yr return p.a.+21.1%+30.4%+20.1%+12.0%+14.7%+19.5%+14.9%
5-yr return p.a.+6.0%+18.3%+6.8%+6.5%+18.7%+9.9%+5.3%
# holdings647780642486401

The fund on this page stays pinned on the left — scroll or use ‹ › to compare it against each one.

Open the full comparison tool →
Data as of 2026-10-22 · Source: issuer data, compiled by Finance Hamster

New to ETFs? Start with the basics →

Finance Hamster provides educational information about ETFs and investing. It is not investment, tax, or legal advice, and not a recommendation to buy or sell any security. Markets carry risk; do your own research or consult a licensed adviser.